Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2017-01-22 Capital/Financing Update
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Regeneus receives upfront payment of US$5.5m from AGC 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 23 January 2017, reporting that Regeneus Ltd has received an upfront payment of US$5.5 million from AGC for exclusive manufacturing rights under a collaboration and license agreement. It mentions expected milestone payments and royalties related to the development and commercialization of a product. The content focuses on a financing event related to licensing and collaboration payments, not on financial results, management changes, or regulatory filings. The document length is short (2502 characters) and it is a clear announcement of a capital-related transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-01-22 English
Q4 2016 Update 4 pages 715.0KB
Investor Presentation Classification · 85% confidence The document is a quarterly update newsletter from Regeneus for Q4 2016. It contains information about strategic collaborations, clinical trial progress, regulatory changes, research agreements, and industry news. It does not contain detailed financial statements or comprehensive financial performance data typical of an Interim/Quarterly Report (IR). Instead, it is more of a business update and news communication to investors and stakeholders. The length is 8808 characters, which is substantial but the content is primarily narrative and update-focused rather than financial reporting. Therefore, the best fitting category is Investor Presentation (IP), as it provides detailed information on company strategy, collaborations, and market positioning for investors.
2017-01-17 English
Regeneus and AGC collaborate on Progenza in Japan 3 pages 239.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 29 December 2016 about a strategic collaboration and licensing agreement between Regeneus and AGC Asahi Glass for the manufacture, clinical development, and commercialization of a stem cell technology product in Japan. It details the terms of the collaboration, financial arrangements, market context, and company backgrounds. There are no financial statements, quarterly or annual results, or regulatory certifications included. The document is a corporate announcement about a capital and strategic partnership rather than a financial report or regulatory filing. It fits best under Capital/Financing Update (CAP) as it discusses a significant financing and collaboration agreement involving milestone payments and joint venture formation.
2016-12-28 English
Trading Halt 1 page 95.0KB
Regulatory Filings Classification · 95% confidence The document is a market release announcing a trading halt for Regeneus Ltd securities pending a future announcement. It does not contain financial data, report content, or detailed information about the company’s financials or management. It is a regulatory announcement related to trading status, not a report or detailed filing. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-12-27 English
Trading Halt Request 1 page 57.5KB
Regulatory Filings Classification · 95% confidence The document is a letter from Regeneus Ltd to ASX Limited requesting a trading halt under Listing Rule 17.1. It explains the reason for the halt is to complete signing transaction documents and prepare a market announcement about a strategic collaboration and licensing agreement. The document is short (1442 characters) and is a formal request for a trading halt, not a financial report or announcement of results. It does not contain financial data, earnings, or management discussion. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement related to trading status rather than a report or detailed financial disclosure.
2016-12-27 English
Appendix 4C - Quarterly 6 pages 492.7KB
Regulatory Filings
2016-10-31 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.